Merck's TroFuse-015 Surpasses Survival Goals
Tap title to read story
Merck & Co.
Inc. (NYSE:MRK) on Friday announced that its pivotal Phase 3 TroFuse-015 trial met its primary endpoint of overall survival (OS).
Evaluating sacituzumab tirumotecan (sac‑TMT), the trial marks the first time a TROP2‑directed ADC improved OS in a global Phase 3 study for locally advanced unresectable or metastatic gastroesophageal adenocarcinoma patients who received two or more prior lines of systemic therapy. sac‑TMT is an investigational TROP2‑directed antibody‑drug conjugate (ADC) licensed from Kelun‑Biotech.
At final analysis, sac‑TMT delivered a statistically significant and clinically meaningful OS improvement compared to treatment of physician’s choice (TPC), which consisted of trifluridine‑tipiracil, irinotecan, paclitaxel, or docetaxel.
Researchers observed generally consistent results across patient subgroups regardless of TROP2 expression status.
However, sac‑TMT did not meet its secondary endpoint of progression‑free survival (PFS).
More context
Timeline
- On November 18 2013 Merck's anti-PD-1 immunotherapy shows 81 percent survival rate in advanced.
- On August 19 2026 Merck and Moderna trial meets recurrence-free survival endpoint for cancer.
- On October 14 2026 Merck reports positive survival data for investigational therapy in advanced.
Coverage notes
Center: Coverage from grafa.com, merck.com, merckgroup.com frames this as a developing news story: Merck's TroFuse-015 Surpasses Survival Goals. Reporting emphasizes verified facts, named sources, and near-term impact for readers. Left: Left-leaning desks covering the same development typically emphasize public impact, institutional accountability, and who is most affected. Right: Right-leaning desks covering the same development typically emphasize practical outcomes, market or security stakes, and institutional response.
Primary report
Benzinga — Merck's TroFuse-015 Surpasses Survival Goals
Sources
JQJO Editorial Desk · Human reviewed · AI assisted. Report a correction.



























